Dual function miR-205 is positively associated with ER and negatively with five-year survival in breast cancer patients

Nina Petrović; Lidija Todorović; Milica Nedeljković; Ana Božović; Zoran Bukumirić; Nasta Dedović Tanić; Snežana Jovanović-Ćupić; Ahmad Šami; Vesna Mandušić

doi:10.1016/j.prp.2022.154080

Dual function miR-205 is positively associated with ER and negatively with five-year survival in breast cancer patients

Pathol Res Pract. 2022 Oct:238:154080. doi: 10.1016/j.prp.2022.154080. Epub 2022 Aug 17.

Authors

Nina Petrović¹, Lidija Todorović², Milica Nedeljković³, Ana Božović², Zoran Bukumirić⁴, Nasta Dedović Tanić⁵, Snežana Jovanović-Ćupić², Ahmad Šami⁶, Vesna Mandušić²

Affiliations

¹ Laboratory for Radiobiology and Molecular Genetics, "VINČA" Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, Serbia; Department for Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
² Laboratory for Radiobiology and Molecular Genetics, "VINČA" Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, Serbia.
³ Department for Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia. Electronic address: mnedel30@tutanota.com.
⁴ Institute for Medical Statistics and Informatics, School of Medicine, University of Belgrade, Belgrade, Serbia.
⁵ Laboratory for Radiobiology and Molecular Genetics, "VINČA" Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, Serbia; Department of Natural Sciences and Mathematics, State University of Novi Pazar, Serbia.
⁶ Cellular and Molecular Radiation Oncology Laboratory, Department of Radiation Oncology, Universitaetsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

PMID: 35994808
DOI: 10.1016/j.prp.2022.154080

Abstract

Background: Precise molecular characterization of breast cancer, especially triple negative (TNBC) as the most lethal subtype, is needed to stratify patients for the individual treatment approach. MicroRNA-205 (miR-205) has tumor-suppressive and oncogenic functions across different cancers. Therefore, miR-205 might have a different role in TNBC and estrogen receptor (ER) positive BC. Our aim was to investigate how miR-205 expression is associated with ER/progesteron receptor status, clinical parameters, pathohistological characteristics of BC, and survival of patients METHODS: We determined miR-205 relative expressions in 73 primary breast tumors (50 TNBC and 23 ER+) by quantitative Real-time polymerase chain reaction (qPCR) and compared it to clinicopathological characteristics and outcome.

Results: The highest levels of miR-205 were in the ER+ /PR+ group, and the lowest in the TNBC group (p = 0.009). Significantly higher levels of miR-205 were also observed in the ER+ compared with the ER-negative group, regardless of the PR status (p = 0.002). Low miR-205 expression level was associated with prognostic stage III in TNBC samples (p = 0.049). Patients who received adjuvant chemotherapy had significantly lower levels of miR-205 (p = 0.016). Patients who received hormone therapy had significantly higher levels of miR-205 (p = 0.007). The low-miR-205 patients had significantly higher 5-year survival rates (p = 0.041).

Conclusion: The expression of miR-205 in BC is subtype-specific and high expression is associated with the ER+ tumors. The miR-205 expression might be a useful marker of TNBC progression. High miR-205 expression had a detrimental effect on BC patient outcome. Our results indicate that miR-205 might be utilized in clinical practice as a biomarker and an adjunct parameter for the selection of the most effective therapeutic modality.

Keywords: Chemotherapy; Estrogen receptor-positive breast cancer; Hormone therapy; MiR-205; Survival; Triple-negative breast cancer.